scispace - formally typeset
Search or ask a question
Institution

Sunovion

CompanyLondon, United Kingdom
About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..


Papers
More filters
Journal ArticleDOI
TL;DR: Focusing on describing test article-related effects on safety pharmacology endpoints, using reasoned arguments as part of an integrated risk assessment, will ensure that the clinical pharmacologists and regulatory bodies see a clear description of relevant findings at each dose or exposure level.

6 citations

Patent
13 Sep 2001
TL;DR: In this article, the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound was described for the treatment and prevention of sexual disorders. But the authors did not specify the dosage forms of these drugs.
Abstract: Methods are disclosed for the treatment and prevention of sexual. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT 3 antagonists.

6 citations

Patent
Yun Gao1, Charles M. Zepp1
19 Jun 1991
TL;DR: In this article, a process for the production of cyclic sulfates and cyclic sulphamidates from the corresponding corresponding Cyclic sulfite and cyclicity sulfamidite substrate, respectively, is described.
Abstract: The invention relates to a process for the production of cyclic sulfates and cyclic sulfamidates from the corresponding cyclic sulfite and cyclic sulfamidite substrate, respectively. The method involves the electrolysis of a solvent mixture containing active metal species, non-metal oxidant species and substrate.

6 citations

Patent
Nancy M. Gray1
22 Sep 1993
TL;DR: In this paper, the authors used optically pure (+) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetririzine.
Abstract: Methods and compositions are disclosed utilizing optically pure (+) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (+) isomer is also useful for the treatment of allergic asthma and chronic and physical urticaria. (+) Cetirizine is an inhibitor of eosinophil chemotaxis and is therefore useful in the treatment of other conditions related to eosinophilia such as allergic asthma, seasonal allergic rhinitis, atopic dermatitis, some parasitic diseases, some chronic obstructive lung diseases and certain gastrointestinal and genitourinary disorders.

6 citations

Journal ArticleDOI
TL;DR: This overview from the Safety Pharmacology Society will outline the strategic plan from 2016 to 2018 and beyond and provide insight into the future of the discipline which builds upon a previous strategic plan established in 2009.

6 citations


Authors

Showing all 572 results

NameH-indexPapersCitations
Chris H. Senanayake5858812142
Paul J. Reider553449827
Antony Loebel422236906
Kenneth S. Koblan40964380
Richard G. Ball371423684
Robert D. Larsen361473544
Robert Goldman351107064
Raymond L. Woosley341153811
Rudy Schreiber33803793
Thomas R. Verhoeven291273135
Andrei Pikalov281202583
David Blum27892958
Mark A. Varney26414032
Lisa DiMichele25881755
John P. Hanrahan25462781
Network Information
Related Institutions (5)
Pfizer
37.4K papers, 1.6M citations

85% related

Eli Lilly and Company
22.8K papers, 946.7K citations

84% related

Merck & Co.
48K papers, 1.9M citations

83% related

Novartis
50.5K papers, 1.9M citations

83% related

Bristol-Myers Squibb
21K papers, 932.5K citations

82% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20222
202146
202049
201932
201834
201751